JPRN-UMIN000036297招募中未知
PADNI: Parkinson's and Alzheimer's disease Dimensional Neuroimaging Initiative - PADNI: Parkinson's and Alzheimer's disease Dimensional Neuroimaging Initiative
atinal Center of Neurology and Psychiatry0 个研究点目标入组 615 人开始时间: 2019年3月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 615
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Existence of significant diseases that may affect the central nervous system other than the target disease of this research, such as neurodegenerative diseases (other than AD/PD related diseases), severe cerebrovascular diseases, neuroimmune diseases, and head injuries. 2) Existence of significant MRI abnormalities, which may affect cognitive function. 3) Drug-induced parkinsonism is likely. 4) SWEDD (Scans Without Evidence of Dopaminergic Deficit). 5) Contraindications to MRI. 6) Hypersensitivity to tracers such as 18F-GE067 and 123I-FP-CIT. 7) Medical history of schizophrenia; major depressive disorder or bipolar disorder defined by DSM-IV within a year. 8) A history of alcoholism and drug dependence defined by DSM-IV within the past two years. 9) Severe mental symptoms that make it difficult to comply with the protocol within the past three months 10) Serious systemic disease or an unstable disease. 11) Systemic disease affecting cognitive function such as infectious disease and metabolic disease. 12)Participant admitted to a nursing home or another hospital. 13) If a participant is planning to participate in a clinical intervention trial at the time of enrollment. 14) Any case in which a researcher or consulting doctor judges that the study is not appropriate for a particular participant.
研究者
相似试验
招募中
2 期
The effects of cannabidiol (CBD) on psychosocial stress, situational anxiety and nausea experienced in a virtual reality environmentPsychosocial stressSituational anxietyCybersicknessMental Health - AnxietyMental Health - Other mental health disordersMotion sicknessACTRN12623000872639niversity of Sydney74
进行中（未招募）
1 期
Tralokinumab monotherapy for adolescent subjects with moderate-to-severe atopic dermatitis - ECZTRA 6Atopic DermatitisMedDRA version: 20.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2017-005143-33-PLEO Pharma A/S301
进行中（未招募）
1 期
A study of mepolizumab (study medicine) as an add-on therapy in subjects with severe uncontrolled asthmaSubjects with severe asthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002513-27-ESGlaxoSmithKline, S.A.544
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, parallel-group, multicenterstudy to demonstrate improvement of symptoms of RLS in subjects withmoderate to severe idiopathic RLS with daytime symptoms who takeoxycodone/naloxone prolonged release (OXN PR) compared to subjects takingplacebo (PLA).Estudio multicéntrico, aleatorizado, con doble anonimato, controlado conplacebo, en grupos paralelos, para demostrar la mejoría de los síntomas delsíndrome de las piernas inquietas (RLS) en pacientes con RLS idiopático, demoderado a grave, con síntomas diurnos, que toman oxicodona/naloxona deliberación prolongada (OXN PR), comparados con el grupo tratado con placebo(PLA).Sindrome de Piernas inquietasRestless Legs SyndromeMedDRA version: 12.0Level: LLTClassification code 10058920Term: Restless legs syndromeEUCTR2009-011107-23-ESMundipharma Research GmbH & Co. KG300
进行中（未招募）
1 期
A study of mepolizumab (study medicine) as an add-on therapy in subjects with severe uncontrolled asthma.Subjects with severe asthmaMedDRA version: 19.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002513-27-EEGlaxoSmithKline Research & Development Ltd544